Publications

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Journal article

Marchevsky NG. et al, (2022), EBioMedicine, 81

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Journal article

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.

Journal article

Ogbe A. et al, (2022), JCI Insight

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Journal article

Clemens SAC. et al, (2021), Nature Communications, 12

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Journal article

Clemens SAC. et al, (2021), Nat Commun, 12

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Journal article

EWER K. et al, (2021), The Lancet

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

Journal article

EWER K. et al, (2021), Lancet HIV

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Journal article

Barrett JR. et al, (2021), Nature medicine

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Journal article

Barrett JR. et al, (2021), Nature medicine

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Frater J. et al, (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Journal article

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Journal article

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Journal article

Emary KRW. et al, (2021), SSRN Electronic Journal

Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.

Journal article

Bach SP. et al, (2021), Lancet Gastroenterol Hepatol, 6, 92 - 105

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Journal article

Voysey M. et al, (2021), The Lancet

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Journal article

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Status of primary and secondary mental healthcare of people with severe mental illness: An epidemiological study from the UK PARTNERS2 programme

Journal article

Reilly S. et al, (2021), BJPsych Open, 7

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Journal article

Barrett JR. et al, (2020), Nat Med

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Journal article

Voysey M. et al, (2020), Lancet